Status:
COMPLETED
Prevalence of Cutaneous Enterococci at Femoral Insertion Site in Transcatheter Aortic Valve Implantation (TAVI)
Lead Sponsor:
Clinique Pasteur
Conditions:
Aortic Valve Disease
Eligibility:
All Genders
18+ years
Brief Summary
The general rules of antibiotic prophylaxis in surgery or interventional medicine include the choice of an antibiotic active on the bacteria most frequently encountered in surgical site infections. Th...
Eligibility Criteria
Inclusion
- Patient scheduled for aortic valve replacement by TAVI procedure with trans femoral approach
- Patient with pre-TAVI assessment performed at Clinique Pasteur
- Patient affiliated or beneficiary of a social security scheme
- Patient accepting to participate and having given his no objection
Exclusion
- TAVI procedure by non-trans femoral approach
- Protected patients: Adults under guardianship or other legal protection; Pregnant or breastfeeding woman; Hospitalized without consent.
Key Trial Info
Start Date :
June 17 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 23 2023
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT04909424
Start Date
June 17 2021
End Date
November 23 2023
Last Update
March 4 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Clinique Pasteur
Toulouse, France, 31076